Multiple Chinese Biopharma Companies Secure Funding in Q2 to Accelerate Innovative Drug Development

　　【Pharmaceutical Network Industry DynamicsRecently, Shunjing Pharmaceutical announced the completion of a 300 million yuan Series A round of financing. This round was led by Songhe Capital, with participation from Dawning Fund, Chuangjing Capital, and Lishui Qiaoda, while Hotgen Biotech continued its support. The funds will mainly be used to accelerate the clinical trials of Shunjing Pharmaceutical's world-first acute myocardial infarction antibody drug SGC001, preclinical applications for the core oncology pipeline SGT003, and to advance the research and development of multiple early-stage pipelines in cardiovascular, oncology, and neurodegenerative diseases, as well as the construction of technical platforms.
 

Public information shows that Beijing Shunjing Biomedical Technology Co., Ltd. is an innovation-driven biopharmaceutical technology company dedicated to the discovery, development, and commercialization of original (FIC, First in class) antibody drugs. With strong scientific research and innovative drug development capabilities, Shunjing has built an international antibody drug R&D platform, focusing on unmet clinical needs and establishing multiple product pipelines of original biomacromolecular drugs with market potential.
 

Among them, SGC001, a globally pioneering antibody drug for treating acute myocardial infarction with rapid R&D progress by the company, has successively obtained approval for clinical trial applications (IND) from the U.S. FDA and the National Medical Products Administration. In March 2025, it was granted Fast Track Designation by the U.S. FDA and is currently undergoing Phase Ib clinical trials at multiple centers across China. Completed clinical studies in healthy subjects have shown that it has good safety and tolerability.
 

SGT003 is a bispecific antibody. Preclinical study data show that SGT003 can significantly reduce the number of Tregs and TAMs. At a lower dose, SGT003 demonstrates better tumor suppression effects compared to marketed anti-PD-1 monoclonal antibodies and anti-CTLA-4 monoclonal antibodies, without stimulating the release of factors such as TNF-α, greatly improving safety and showcasing significant advantages in tumor treatment. In addition, after treatment with SGT003, animal bodies can acquire anti-tumor immune memory, effectively preventing tumor recurrence. SGT003 has the potential to become a more effective and safer first-line cornerstone drug for next-generation cancer immunotherapy.
 

Apart from Beijing Shunjing Biomedical Technology Co., Ltd., a group of pharmaceutical companies have also announced the completion of financing since Q2 2025, with funds similarly allocated to accelerate new drug development and more.
 

For example, on May 29, AusperBio announced the completion of a $50 million Series B+ financing round. This round was led by a globally renowned industry investment institution, with participation from Qiming Venture Partners, CDH VGC, Genesis Capital, Oriza Ventures, HanchorBio Capital, and Sherpa Healthcare Partners. The proceeds from the financing will primarily be used to support the ongoing clinical development of its innovative antisense oligonucleotide drug AHB-137 for the functional cure of chronic hepatitis B (CHB), including the planned Phase II clinical trials to be conducted outside mainland China. Additionally, the funds will be utilized to expand commercial production partnerships and advance the expansion of the product pipeline.
 

On May 20, CureGene announced the completion of an oversubscribed Series B+ financing round totaling over RMB 100 million. The proceeds from this financing will primarily be used to advance the Phase III clinical development of its core cardiovascular and cerebrovascular product, CG-0255. CG-0255, a next-generation antiplatelet drug independently developed by CureGene, is an innovative platelet P2Y12 receptor antagonist that utilizes a newly designed metabolic pathway. Clinical data has demonstrated its potential to be a Best-in-Class therapy.
 

On April 11, Ruijian Pharmaceutical announced the completion of its B+ round of financing, with the total amount of B-round financing exceeding 200 million yuan. This round of financing was led by Fengchuan Capital, with participation from Hetang Ventures. The funds raised will be used to accelerate the clinical advancement of the company's Parkinson's disease treatment products NouvNeu001/NouvNeu003 and ophthalmic treatment product NouvSight001 in both China and the United States. Additionally, it will strengthen the development of multiple innovative pipelines and the establishment of clinical capabilities, as well as enhance the company’s industrialization efforts.
 

　　......
 

The surge in pharmaceutical companies' financing in the second quarter highlights the strong momentum of innovative drug development, ranging from acute myocardial infarction, cancer, hepatitis B cure, to neurological disorders. Capital is increasingly flowing towards original therapies with high clinical value and strong technological barriers. As major companies secure funding and advance their pipelines, the innovation vitality and internationalization process of the biopharmaceuticals industry are expected to further accelerate, injecting new impetus for treatment breakthroughs across more disease areas.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.